Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6390938 | 0.91 | ESR1 (0.37) | ESR1ESR2KDM4EMEN1ALDH1A1 | |
| SCHEMBL13561414 | 0.91 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL225186 | 0.91 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL29352110 | 0.91 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL6395748 | 0.82 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL4416261 | 0.81 | ESR1 (0.36) | ESR1ESR2MEN1KMT2ATERT | |
| SCHEMBL4712395 | 0.80 | ALDH1A1 (0.36) | MEN1ALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL29761239 | 0.80 | CHRNB2 (0.46) | ESR1ESR2 | |
| SCHEMBL3564889 | 0.80 | CHRNB2 (0.46) | ESR1ESR2 | |
| SCHEMBL4689632 | 0.79 | CHRNB2 (0.41) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1044189-B2 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-1619192-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-1383733-B1 | PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1044189-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070275973-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER INC | 2007-11-29 | — | — | US | disclosed |
| US-7205300-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2007-04-17 | — | — | US | disclosed |
| US-7186870-B2 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | PFIZER INC (US) | 2007-03-06 | — | — | US | disclosed |
| US-7144882-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-12-05 | — | — | US | disclosed |
| US-7091372-B2 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | PFIZER INC (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1259489-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1259489-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002085843-A2 | PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020132824-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2002-09-19 | — | — | US | disclosed |
| US-20020111350-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2002-08-15 | — | — | US | disclosed |
| US-6410550-B1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2002-06-25 | — | — | US | disclosed |
| US-20020072524-A1 | Aryl fused azapolycyclic compounds | WADSWORTH JOTHAM (US) | 2002-06-13 | — | — | US | disclosed |
| US-20020072525-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2002-06-13 | — | — | US | disclosed |
| WO-2001062736-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| EP-1044189-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999035131-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132824-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | ESR1 3094/4885ESR2 1196/4885KDM4E 1202/4885 |
| US-20020072524-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | ESR1 3094/4885ESR2 1196/4885KDM4E 1202/4885 |
| US-20020111350-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | ESR1 3094/4885ESR2 1196/4885KDM4E 1202/4885 |
| US-20070275973-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | GRIN2C, GRIN2A, GRIN2B | ESR1 1981/4885ESR2 1248/4885KDM4E 1143/4885 |
| US-20020072525-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | ESR1 3094/4885ESR2 1196/4885KDM4E 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.